Apexigen Revenue and Competitors
Estimated Revenue & Valuation
- Apexigen's estimated annual revenue is currently $2.1M per year.
- Apexigen's estimated revenue per employee is $100,500
- Apexigen's total funding is $158M.
Employee Data
- Apexigen has 21 Employees.
- Apexigen grew their employee count by -34% last year.
Apexigen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Business Development | Reveal Email/Phone |
2 | SVP, Finance and Operations | Reveal Email/Phone |
3 | SVP CMC | Reveal Email/Phone |
4 | Head Clinical Operations | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Chief Medical Officer and SVP, Clinical Development | Reveal Email/Phone |
7 | Senior Director Project Management | Reveal Email/Phone |
8 | Senior Director, Regulatory Affairs | Reveal Email/Phone |
9 | Director Quality Assurance | Reveal Email/Phone |
10 | Exexutive assistant to CEO/Office Manager | Reveal Email/Phone |
Apexigen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Apexigen?
Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMABￃﾢ￢ﾀﾞￂﾢ, the Companyￃﾢ￢ﾂﾬ￢ﾄﾢs proprietary antibody drug discovery platform. Its lead immuno-oncology drug candidate, APX005M, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.
keywords:Biotechnology
$158M
Total Funding
21
Number of Employees
$2.1M
Revenue (est)
-34%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Apexigen News
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients...
SAN CARLOS, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Apexigen, ... Apexigen's monoclonal antibody targeting CD40, in combination with...
SAN CARLOS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Apexigen, ... Apexigen's monoclonal antibody targeting CD40, in combination with...
SAN CARLOS, Calif., April 9, 2021 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced two upcoming poster presentations accepted as late breaking abstracts at th ...
SAN CARLOS, Calif., Nov. 9, 2020 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced two upcoming poster presentations at the 35th Society for Immunotherapy of C ...
Other Companies in San Carlos
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.4M | 22 | -19% | N/A |
#2 | N/A | 23 | -4% | N/A |
#3 | $2.3M | 23 | -8% | N/A |
#4 | $2.3M | 23 | -8% | N/A |
#5 | $1.9M | 24 | -23% | $80M |